Yuhan's YH35995 Receives FDA Orphan Drug Designation for Gaucher Disease Treatment
Key Insights
Yuhan Corporation (search)'s investigational drug YH35995 has received FDA orphan drug designation for treating Gaucher disease (search), a rare inherited lysosomal storage disorder (search).
The oral small-molecule drug inhibits glucosylceramide synthase (search) and has demonstrated ability to cross the blood-brain barrier in preclinical studies.
Type 3 Gaucher disease (search) currently has no approved treatments, representing a significant unmet medical need with neurological symptoms.
Yuhan Corporation (search) announced that its investigational drug YH35995 has received orphan drug designation from the US Food and Drug Administration for the treatment of Gaucher disease (search), a rare inherited lysosomal storage disorder (search). The designation underscores the significant unmet medical need for patients with this condition, particularly those with Type 3 Gaucher disease (search) who experience neurological symptoms.
Addressing Critical Treatment Gap
Gaucher disease (search) is a rare inherited lysosomal storage disorder (search) caused by enzyme deficiency, leading to symptoms including enlarged liver and spleen, anemia (search), thrombocytopenia (search) and skeletal complications. Type 3 Gaucher disease (search) presents additional challenges as it involves neurological symptoms and currently has no approved treatment options available.
The FDA orphan drug designation is granted to therapies targeting rare diseases with limited treatment options, offering valuable incentives including tax credits for clinical trials, exemption from FDA review fees and up to seven years of market exclusivity upon approval.
Novel Mechanism of Action
YH35995 is an oral small-molecule drug designed to inhibit glucosylceramide synthase (search), functioning as a substrate reduction therapy that suppresses the production of glucosylceramide. In preclinical studies, the compound demonstrated the ability to penetrate the blood-brain barrier and reduce glucosylceramide production, positioning it as a promising candidate for Type 3 Gaucher disease (search) patients with neurological symptoms.
The drug's ability to cross the blood-brain barrier and consistently inhibit glucosylceramide in the brain represents a significant advancement for addressing the neurological manifestations of Type 3 Gaucher disease (search).
Clinical Development Progress
Prior to securing the FDA designation, Yuhan obtained approval from Korea's Ministry of Food and Drug Safety to begin clinical trials. The company is currently conducting first-in-human studies to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults.
"The designation highlights both the urgent need for new treatments for Gaucher disease (search) and the potential of YH35995," said Kim Yeol-hong, head of R&D at Yuhan. "We will expedite clinical development in coordination with global regulators and aim to deliver new therapeutic options for patients with rare diseases."
Strategic Development Plans
Following the orphan drug designation, Yuhan plans to accelerate global development and advance regulatory strategies to improve patient access. The company emphasized its commitment to working with global regulatory agencies to provide meaningful treatment alternatives for patients with rare diseases.
Kim Yeol-hong noted that the FDA designation represents "a meaningful achievement that confirms both the need for treatment options for Type 3 Gaucher disease (search) patients and the potential of YH35995."